+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials



Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials



Ophthalmology 123(4): 858-864



To describe morphologic and visual outcomes in eyes with angiographic cystoid macular edema (CME) treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration (nAMD). Prospective cohort study within a randomized clinical trial. A total of 1185 CATT study subjects. Baseline fluorescein angiography (FA) images of all CATT study eyes were evaluated for CME. Grading of other characteristics on optical coherence tomography (OCT) and photographic images at baseline and during 2-year follow-up was completed by readers at the CATT Reading Centers. Three groups were created on the basis of baseline CME and intraretinal fluid (IRF) status: (1) CME, (2) IRF without CME, (3) neither CME nor IRF. Visual acuity (VA) and total central retinal thickness (CRT) on OCT at baseline, year 1, and year 2. Among 1131 participants with images of sufficient quality for determining CME and IRF at baseline, 92 (8.1%) had CME, 766 (67.7%) had IRF without CME, and 273 (24.1%) had neither. At baseline, eyes with CME had worse mean VA (letters) than eyes with IRF without CME and eyes with neither CME nor IRF (52 vs. 60 vs. 66 letters, P < 0.001); higher mean total CRT (μm) on OCT (514 vs. 472 vs. 404, P < 0.001); and greater hemorrhage, retinal angiomatous proliferation (RAP) lesions, and classic choroidal neovascularization (CNV). All groups showed improvement in VA at follow-up; however, the CME group started and ended with the worst VA among the 3 groups. Central retinal thickness, although higher at baseline for the CME group, was similar at 1 and 2 years follow-up for all groups. More eyes with CME (65.3%) developed scarring during 2 years of follow-up compared with eyes with IRF without CME (43.8%) and eyes with neither CME nor IRF (32.5%; P < 0.001). In CATT, eyes with CME had worse baseline and follow-up VA, although all groups showed similar rates of improvement in VA during 2 years of follow-up. Cystoid macular edema seems to be a marker for poorer visual outcomes in nAMD because of underlying baseline retinal dysfunction and subsequent scarring.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057199461

Download citation: RISBibTeXText

PMID: 26778329

DOI: 10.1016/j.ophtha.2015.11.030


Related references

Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123(8): 1751-1761, 2016

Anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: Comparison of Age-related Macular Degeneration Treatments Trials 5 year outcomes and implication for clinical practice. Clinical and Experimental Ophthalmology 45(4): 333-335, 2017

Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmology 134(6): 674-681, 2016

Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123(7): 1530-1540, 2016

Macular degeneration related to age and cystoid macular edema. Apropos of 95 cases (100 eyes). Journal Francais d'Ophtalmologie 11(11): 711-720, 1988

Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Archives of Ophthalmology 120(6): 731-737, 2002

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120(9): 1860-1870, 2013

Cystoid macular edema is a common finding in patients with choroidal neovascular membrane associated with age-related macular degeneration. IOVS 41(4): S162, 2000

Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123(4): 865-875, 2016

Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology 126(2): 252-260, 2019

Impact of fluorescein angiographic characteristics of macular lesions on outcomes after macular translocation 360 degree surgery in eyes with age-related macular degeneration. Retina 25(5): 597-607, 2005

Cystoid Macular Edema and Cystoid Macular Degeneration as a Result of Multiple Pathogenic Factors in the Setting of Central Serous Chorioretinopathy. Retinal Cases and Brief Reports 11(Suppl. 1): S197-S201, 2016

Comparison of evaluation parameters in the retinal layer between diabetic cystoid macular edema and postoperative cystoid macular edema after cataract surgery based on a hierarchical approach. Technology and Health Care 24(Suppl. 1): S59-S68, 2015

Effect of Intraocular Pressure-Lowering Medications on Neovascular Age-Related Macular Degeneration Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatment Trials. Retina 39(4): 636-647, 2019

Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 122(6): 1203-1211, 2015